Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd.: Capital raising of $4M will support the company's clinical and strategic goals; price target unchanged

This publication is part of Frost & Sullivan's independent equity research service TEL AVIV, Israel, Feb. 2, 2018 /PRNewswire/ -- Summary of Highlights * On January 29, 2018, Cellect announced that it had entered into a securities purchase agreement with certain institutional investors for gr...